No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

• Adlai Nortye Ltd.
• Achieve Life Sciences, Inc.
• Allogene Therapeutics, Inc.
• Zhejiang Wecome Pharmaceutical Company Limited
• Phathom Pharmaceuticals, Inc.
• Hvsen Biotechnology Co., Ltd.
• Esperion Therapeutics, Inc.
• Zevra Therapeutics, Inc.